

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
28 December 2017 (28.12.2017)



(10) International Publication Number
WO 2017/223111 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C12N 15/13 (2006.01)
C07K 16/46 (2006.01)

(21) International Application Number:

PCT/US2017/038373

(22) International Filing Date:

20 June 2017 (20.06.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/352,698 21 June 2016 (21.06.2016) US
62/394,360 14 September 2016 (14.09.2016) US
62/491,908 28 April 2017 (28.04.2017) US

(71) Applicant: **TENEOBIO, INC.** [US/US]; 1490 O'Brien Drive, Suite D, Menlo Park, California 94025 (US).

(72) Inventors: **TRINKLEIN, Nathan**; 2302 Hopkins Ave., Redwood City, California 94062 (US). **VANSCHOOTEN, Wim**; 1444 Floyd Avenue, Sunnyvale, California 94087 (US). **ALDRED, Shelley Force**; 23860 Twin Creeks Court, Hayward, California 94541 (US). **HARRIS, Katherine**; 3305 Kipling Place, Fremont, California 94536 (US). **PHAM, Duy**; 550 Lily Ann Way, San Jose, California 95123 (US).

(74) Agent: **SHERWOOD, Pamela J.**; Bozicevic, Field & Francis LLP, 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94065 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: CD3 BINDING ANTIBODIES

FIG. 1B

312325	SEQ ID NO:19	QSVSSN	GAS	QQYNNWPWT
308902-bivalent	SEQ ID NO:20	GFTVSSYG	IRGSDGST	AKQGENDGPFDPH
308902	SSEQ ID NO:21	GFTVSSYG	IRGSDGST	AKQGENDGPFDPH

(57) Abstract: The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.

WO 2017/223111 A1